Biobypass

(redirected from Angiogen)

Biobypass

A gene-based drug delivery product that promotes angiogenesis in tissues with poor blood flow—e.g., in patients with CAD and peripheral vascular disease.

Biobypass®

Cardiology A gene-based drug delivery product that promotes angiogenesis in tissues with poor blood flow–eg, in Pts with CAD and and peripheral vascular disease. See Angiogenesis.
References in periodicals archive ?
39) The green tea polyphenol EGCG shows evidence of decreasing the drug resistance phenotype in certain cancer cells and inhibiting angiogen isis.
The company combines its patented gene transfer technologies with proprietary therapeutic genes to create product candidates, such as BioBypass angiogen for cardiovascular disease, TNFerade for cancer and AdPEDF for macular degeneration and diabetic retinopathy.
GenVec's lead cardiovascular product candidate is BioBypass angiogen, which is in late-stage randomized Phase II studies in collaboration with Pfizer, Inc.
BIOBYPASS angiogen is now in Phase II clinical trials for the treatment of coronary artery disease and peripheral vascular disease and is being developed in collaboration with Pfizer, Inc.
The company combines its patented gene transfer technologies with proprietary the>rapeutic genes to create product candidates, such as BIOBYPASS angiogen and GENSTENT biologic that address medical needs in the areas of cardiovascular disease, TNFerade biologic for oncology and the PEDF program for ophthalmology.
Community College System, the NC Research Campus houses operations from companies like Anatomics, Angiogen, Carolinas Healthcare System and Red Hat.
This patent adds an additional layer of proprietary protection for our growing product portfolio, that includes our therapeutic angiogenesis product candidate, BIOBYPASS angiogen, which is now in Phase II clinical studies for the treatment of coronary artery disease.
North Carolina Research Campus Inks Deal with Angiogen, LLC
But Platten had his own funding through the privately held Australian company Angiogen Pharmaceuticals, so Steinman was game to see where the idea could go.
Before joining Gryffindor, Fuchs was a founding shareholder of several biotech companies, including Angiogen LLC and Nace Pharma LLC.
The company combines its patented gene transfer technologies with proprietary therapeutic genes to create product candidates, such as BIOBYPASS(R) angiogen and GENSTENT(TM) biologic, that address medical needs in the area of cardiovascular disease, TNFerade(TM) biologic for oncology and the PEDF program for ophthalmology.
GenVec's lead product candidate, BIOBYPASS angiogen, is currently in Phase II clinical trials for the treatment of coronary artery disease and peripheral vascular disease.